start of the meeting, to allow additional time to clear security. Security measures include the following:

• Presentation of a government issued photographic identification to the Federal Protective Service or Guard Service personnel.

• Inspection, via metal detector or other applicable means, of all persons entering the building. We note that all items brought into HHH Building, whether personal or for the purpose of presentation or to support a presentation, are subject to inspection. We cannot assume responsibility for coordinating the receipt, transfer, transport, storage, set up, safety, or timely arrival of any personal belongings or items used for presentation or to support a presentation.

Note: Individuals who are not registered in advance will not be permitted to enter the building and will be unable to attend the meeting.

V. Transcripts

As soon as a transcript of the public meeting is available, it will be accessible on *www.regulations.gov.* A transcript also will be available in either hardcopy or on CD–ROM, after submission of a Freedom of Information request. Written requests are to be sent to the PHS FOIA Office, 7700 Wisconsin Avenue, Suite #920, Bethesda, MD 20857; phone: (301) 492–4800; fax: (301) 492–4848; email: *FOIARequest@psc.hhs.gov.*

VI. Collection of Information

This document does not impose information collection requirements, that is, reporting, recordkeeping or third-party disclosure requirements. All information will be received subsequent to a general solicitation of comments in the **Federal Register** or solicited at or in connection with a public hearing or meeting, thereby making the information collection requests in accordance with the implementing regulations of the PRA at 5 CFR 1320.3(h)(4) and 5 CFR 1320.3(h)(8), respectively. Consequently, there is no need for review by the Office of Management and Budget under the authority of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq*).

Dated: May 20, 2019.

Charles N.W. Keckler,

Associate Deputy Secretary, Immediate Office of the Secretary.

[FR Doc. 2019–10911 Filed 5–23–19; 8:45 am]

BILLING CODE 4150–03–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Findings of research misconduct have been made against William W. Cruikshank, Ph.D. (Respondent), former Professor of Medicine, Pulmonary Center, Boston University (BU) School of Medicine. Dr. Cruikshank engaged in research misconduct in research supported by National Cancer Institute (NCI), National Institutes of Health (NIH), grant R01 CA122737–01A2. The administrative actions, including debarment for a period of five (5) years, were implemented beginning on May 13, 2019, and are detailed below.

FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr. P.H., Interim Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8200.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

William W. Cruikshank, Ph.D., Boston University School of Medicine: Based on the report of an investigation conducted by BU and analysis conducted by ORI in its oversight review, ORI found that Dr. William W. Cruikshank, former Professor of Medicine, Pulmonary Center, BU School of Medicine, engaged in research misconduct in research supported by NCI, NIH, grant R01 CA122737–01A2.

ORI found that Respondent engaged in research misconduct by knowingly, intentionally, and/or recklessly falsifying and/or fabricating data included in the following published paper, an earlier version of the submitted manuscript, a seminar presentation, and two grant applications submitted to NCI, NIH:

• *J. Clin. Invest.* 2011;121:4838–49 (hereafter referred to as ''*JCI* 2011''). Retracted in *J. Clin. Invest.* 2014;124(11):5085.

• Manuscript submitted to *J. Clin. Invest.* (hereafter referred to as the ''*JCI* manuscript'').

• Cruikshank, W. ''A New Look at T Cell Cancers: A Case Study of Translational Research.'' Presented at the Clinical Research Training (CREST) Seminar Series on 09/08/09 (hereafter referred to as the ''CREST Presentation'').

• R01 CA122737–01A1 and R01 CA122737–01A2.

Respondent knowingly, intentionally, and recklessly falsified and/or fabricated Western blot data for protein expression in primary CD4+ T cells from patients with advanced T-cell acute lymphocytic leukemia (T–ALL) or cutaneous T-cell lymphomas (CTCL), by copying blot band images from unrelated sources, manipulating to disguise their origin, and combining multiple images to generate new figures to falsely represent results using sixty-four (64) such band images in the following sixteen (16) figures and related text included in one (1) manuscript, one (1) published paper, two (2) grant applications, and a seminar presentation:

• Figures 1 and 3 in *JCI* 2011, also included as Figure 3 (top and bottom right) in R01 CA122737–01A2 and as Figures 1 and 4 in the initial *JCI* manuscript, respectively
• Figure 8B in *JCI* 2011, also included as Figure 9 in R01 CA122737–01A2
• Figure 9 in *JCI* 2011
• Figures 14A and 14B in R01 CA122737–01A2, also included as Figure 14B in R01 CA122737–01A1
• Figure 4 in R01 CA122737–01A2, also included as Figure 4 in R01 CA122737–01A1
• Slides 24, 25, and 29 in the CREST Presentation

Specifically:

• In Figure 3 in *JCI* 2011, also included as Figure 4 in the *JCI* manuscript and Slide 24 of the CREST Presentation (with no white spaces between bands) as well as Figure 3 (top right section with the tubulin panel flipped 180° clockwise) in R01 CA122737–01A2, the respondent reused a single Western blot band image to represent expression of tubulin and Pro-IL–16 in more than one experimental and control subjects.

• In Figure 1 in *JCI* 2011, also included as Figure 1 in the *JCI* manuscript, Figure 3 (bottom panel) in R01 CA122737–01A2, and in Slide 25 of the CREST Presentation, the respondent copied blot band images from unpublished and/or previously published unrelated experiments and reused a single Western blot band image to falsely represent expression of p27Kip1 and Skp2 in more than one CTCL Patient.

• The respondent reused and relabeled blot band images from unpublished and/or previously published unrelated experiments to falsely represent new experimental results as follows:

➢ Four band images from the unpublished and unrelated figure

''CSC × 24 hrs'' to represent Skp2 protein expression in CTCL Patients

➢ Six band images from Figure 5B in a paper published in *Biochemistry*[1] to represent Actin protein expression in eight (8) CTCL Patients, one (1) T–ALL Patient, and two (2) normal subjects in Figure 1 of *JCI* 2011 and Figure 3 (bottom panel) in R01 CA122737–01A2

• In Figure 8B (bottom part) in *JCI* 2011, also included as Figure 9 in R01 CA122737–01A2 and Slide 29 in the CREST Presentation, respondent falsely reused β-actin, Laminin B, alpha-tubulin, GFP-Pro-IL–16 and HSC70 band images of ''Knockdown of HSC70 in Jurkat cells and Hut78 cells'' as from Normal Human Patient and Normal Subject T-cells.

• In Figure 14A in R01 CA122737–01A2, respondent falsely reused GFP-Pro-IL–16 band images of ''Knockdown of HSC70 in Jurkat cells'' as AKT and phospho-AKT expression and the nuclear Pro-IL–16 band images from Figure 5B in *Biochemistry* 2002 as FOXO1 protein expression in human T-cells stimulated with IL–16.

• In Figure 14B in R01 CA122737–01A1 and R01 CA122737–01A2, respondent falsely reused band images from Figure 5B in *Biochemistry* 2002 that represents Anti-pro IL6 and Anti-Tubulin to represent FOXO1 protein expression in human T-cells.

• In Figure 9 in *JCI* 2011, respondent falsely reused band images representing CD26–T cells of CTCL Patient to also represent normal human subject control for CD26+ and control for CD26–T cells in the same figure.

• In Figure 5 in R01 CA122737–01A1, also included as Figure 4 in R01 CA122737–01A2, respondent reused and falsely relabeled band images within the same figure to represent different experimental conditions.

Respondent intentionally, knowingly, and recklessly falsified and/or fabricated Western blot data for siRNA knockdown of Heat shock cognate 71 kDa protein (HSC70) in Jurkat cells purportedly with two different siRNA constructs, by reusing and relabeling ten (10) band images from experiments on Hut78 cells and a failed experiment in Jurkat cells, and included them in four (4) figures in one manuscript, one published paper, one grant application, and one presentation.

Specifically, respondent reused band images of an unpublished Western blot figure, by:

• Reusing results of a single HSC70 siRNA knockdown on Hut78 cells and relabeling them to represent data from Jurkat cells in Figure 6 in the first submission of the *JCI* manuscript, Figure 6 in *JCI* 2011, and Figure 10 in R01 CA122737–01A2 (also included as Slide 27 in the CREST Presentation)

• reusing results for a second siRNA construct that failed to knockdown HSC70 in Jurkat cells and relabeling them as from control samples in Figure 6 in *JCI* 2011

Dr. Cruikshank entered into a Voluntary Exclusion Agreement (Agreement) and voluntarily agreed for a period of five (5) years, beginning on May 13, 2019:

(1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility for or involvement in nonprocurement programs of the United States Government referred to as ''covered transactions'' pursuant to HHS' Implementation (2 CFR part 376) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the ''Debarment Regulations''); and

(2) to exclude himself from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

Wanda K. Jones,

Interim Director, Office of Research Integrity.

[FR Doc. 2019–10874 Filed 5–23–19; 8:45 am]

BILLING CODE 4150–31–P

[1] Wilson KC, Cruikshank WW, Center DM, Zhang Y. Prointerleukin-16 contains a functional CcN motif that regulates nuclear localization. *Biochemistry* 2002;41:14306–14312 (hereafter referred to as ''*Biochemistry* 2002'').

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Amended Notice of Meeting

Notice is hereby given of a change in the joint meeting of the National Cancer Advisory Board and NCI Board of Scientific Advisors, June 10, 2018, 8:30 a.m. to June 11, 2018, 12:00 p.m., National Cancer Institute Shady Grove Campus, Rockville, MD 20850 which was published in the **Federal Register** on February 11, 2019, 84 FR 3312.

This meeting notice is amended to add two subcommittee meetings on Sunday, June 9, 2019. The National Cancer Advisory Board (NCAB) Ad Hoc Subcommittee on Population Science, Epidemiology and Disparities will meet on June 9, 2019 from 5:30 p.m. to 7:00 p.m. and the NCAB Subcommittee on Planning and Budget will meet on June 9, 2019 from 7:30 p.m. to 9:00 p.m. at the Gaithersburg Marriott Washingtonian Center, 9751 Washington Boulevard, Room—To Be Determined, Gaithersburg, MD 20878.

This meeting notice is also amended to change the meeting from a two-day to a one-day meeting, correct the year, and change the closed session agenda. The joint meeting of the NCAB and NCI Board of Scientific Advisors will now be held on June 10, 2019 with the open session from 8:30 a.m. to 4:45 p.m. and the closed session from 5:00 p.m. to 6:00 p.m. The closed session agenda is corrected to be the Review of NCAB grant applications. The meeting is partially Closed to the public.

Dated: May 21, 2019.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019–10943 Filed 5–23–19; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be held as a teleconference only and is open to the public to dial-in for participation. Individuals who plan to dial-in to the meeting and need special assistance or other reasonable accommodations in order to do so, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: National Cancer Institute Clinical Trials and Translational Research Advisory Committee; Translational Research Strategy Subcommittee (TRSS).

Date: June 19, 2019,

Time: 10:00 a.m. to 11:00 a.m.

Agenda: Review the Glioblastoma (GBM) Working Group Report.

Place: National Cancer Institute Shady Grove, Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850 (Telephone Conference Call), Phone: 240–276–6500, Conference Code: 1102766460, Passcode: 6460.

Contact Person: Peter Ujhazy, MD, Ph.D., Deputy Associate Director, Translational Research Program, Division of Cancer Treatment and Diagnosis, National Institutes of Health, National Cancer Institute, 9609 Medical Center Drive, Room 3W106, Rockville, MD 20850, 240–276–5681, *ujhazyp@mail.nih.gov*.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on